Skip to Content
Merck
CN

The role of cancer stem cells in the anti-carcinogenicity of curcumin.

Molecular nutrition & food research (2013-08-01)
Leonie Norris, Ankur Karmokar, Lynne Howells, William P Steward, Andreas Gescher, Karen Brown
ABSTRACT

Many cancers contain cell subpopulations that display characteristics of stem cells. These cells are characterised by their ability to self-renew, form differentiated progeny and develop resistance to chemotherapeutic strategies. Cancer stem cells may utilise many of the same signalling pathways as normal stem cells including Wnt, Notch and Hedgehog. The dietary agent curcumin exerts a plethora of anti-carcinogenic effects both in vitro and in vivo, and can also inhibit many of the signalling pathways associated with stem cell biology. Emerging evidence suggests that curcumin can exert its anti-carcinogenic activity via targeting cancer stem cells through the disruption of stem cell signalling pathways. In this review we summarise the ability of curcumin to interfere with signalling pathways Wnt, Hedgehog, Notch, Signal Transducers and Activator (STAT) and interleukin-8, and report curcumin-induced changes in function and properties of cancer stem cells. We present evidence that the effects of curcumin on cancer stem cells mediate, or contribute to, its anti-carcinogenic activity.

MATERIALS
Product Number
Brand
Product Description

USP
Curcumin, United States Pharmacopeia (USP) Reference Standard
Supelco
Curcumin, analytical standard
Curcumin, primary reference standard
Sigma-Aldrich
Curcumin, ≥94% (curcuminoid content), ≥80% (Curcumin)
Sigma-Aldrich
Curcumin, from Curcuma longa (Turmeric), powder
Supelco
Curcumin, suitable for matrix substance for MALDI-MS, ≥99.5% (HPLC)